enGene Therapeutics (FRA:S0N0) Accounts Payable: €1.53 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:S0N0 enGene Therapeutics Inc FRA:S0N0
19 GF Score
Price €1.43
! 1 Warning Sign
View Full Analysis

What is enGene Therapeutics Accounts Payable?

enGene Therapeutics FRA:S0N0 -2.05% 19 Accounts Payable is €1.53 Mil as of Apr. 2026. GuruFocus rates FRA:S0N0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

enGene Therapeutics's Accounts Payable for the quarter that ended in Apr. 2026 was €1.53 Mil.

enGene Therapeutics's quarterly Accounts Payable declined from Oct. 2025 (€5.75 Mil) to Jan. 2026 (€2.07 Mil) and declined from Jan. 2026 (€2.07 Mil) to Apr. 2026 (€1.53 Mil).

enGene Therapeutics's annual Accounts Payable increased from Oct. 2023 (€1.10 Mil) to Oct. 2024 (€1.30 Mil) and increased from Oct. 2024 (€1.30 Mil) to Oct. 2025 (€5.75 Mil).

enGene Therapeutics Accounts Payable Related Terms

enGene Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for enGene Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

enGene Therapeutics Accounts Payable Chart

enGene Therapeutics Annual Data
Trend Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Accounts Payable
Get a 7-Day Free Trial 0.86 0.73 1.10 1.30 5.75

enGene Therapeutics Quarterly Data
Oct21 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.40 2.04 5.75 2.07 1.53
FRA:S0N0
19GF Score
enGene Therapeutics Inc FRA:S0N0
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

enGene Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €1.53 Mil mean?
enGene Therapeutics (FRA:S0N0) has a Accounts Payable of €1.53 Mil as of Apr. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on enGene Therapeutics and its competitors.
Is enGene Therapeutics' Accounts Payable too high?
enGene Therapeutics' current Accounts Payable is €1.53 Mil. Overall, enGene Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' Accounts Payable compare to VTVT and GUTS?
enGene Therapeutics' Accounts Payable of €1.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on enGene Therapeutics and its competitors. enGene Therapeutics's current Accounts Payable is €1.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (FRA:S0N0) has a current Accounts Payable of €1.53 Mil. The current Accounts Payable is €1.53 Mil. enGene Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For enGene Therapeutics (FRA:S0N0), the current Accounts Payable is €1.53 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

enGene Therapeutics Business Description

Other Exchanges ENGN:USA
Address 4868 Rue Levy, Suite 220, Saint-Laurent, QC, CAN, H4R 2P1
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
19GF Score

Get the complete analysis for FRA:S0N0

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.43
Price